Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CTIX-1807
- Development stage
- Preclinical
- Lead developer
- Innovation Pharmaceuticals
- Modality
- Small Molecules
01
Overview
**CTIX-1807** is a synthetic host defense protein mimetic (defensin mimetic) developed by Cellceutix (now Innovation Pharmaceuticals) as an antimicrobial agent targeting carbapenem-resistant Enterobacteriaceae (CRE), particularly **Klebsiella pneumoniae**. It demonstrated robust activity in a mouse tissue infection model against CRE organisms, addressing critical gram-negative bacterial infections resistant to carbapenem antibiotics. Initial research focused on advancing lead compounds like CTIX-1807 for CRE, with potential applications in otic (ear) infections as antifungal formulations under evaluation for ototoxicity.[1][4][7][10][16]
Beyond the preview
Go deeper on CTIX-1807.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CTIX-1807.